Hematologic Manifestations of Deficiency of Adenosine Deaminase 2 (DADA2) and Response to Tumor Necrosis Factor Inhibition in DADA2-Associated Bone Marrow Failure

J Clin Immunol. 2018 Feb;38(2):166-173. doi: 10.1007/s10875-018-0480-4. Epub 2018 Feb 6.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenosine Deaminase / deficiency*
  • Anemia, Aplastic / diagnosis
  • Anemia, Aplastic / drug therapy*
  • Anemia, Aplastic / etiology*
  • Biomarkers
  • Biopsy
  • Bone Marrow / pathology
  • Bone Marrow Diseases / diagnosis
  • Bone Marrow Diseases / drug therapy*
  • Bone Marrow Diseases / etiology*
  • Bone Marrow Failure Disorders
  • Hematologic Tests
  • Hemoglobinuria, Paroxysmal / diagnosis
  • Hemoglobinuria, Paroxysmal / drug therapy*
  • Hemoglobinuria, Paroxysmal / etiology*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Intercellular Signaling Peptides and Proteins / deficiency*
  • Male
  • Middle Aged
  • Severe Combined Immunodeficiency / diagnosis
  • Severe Combined Immunodeficiency / etiology
  • Symptom Assessment
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / therapeutic use*

Substances

  • Biomarkers
  • Immunosuppressive Agents
  • Intercellular Signaling Peptides and Proteins
  • Tumor Necrosis Factor-alpha
  • ADA2 protein, human
  • Adenosine Deaminase